EVIDENCE-BASED REVIEW
Treatments for pulmonary arterial hypertension☆

https://doi.org/10.1016/j.rmed.2006.01.021Get rights and content
Under an Elsevier user license
open archive

Summary

Pulmonary arterial hypertension (PAH) is a devastating disease that leads to right heart failure and premature death. Historically, we are restricted by limited options for drug treatment. Over the past decade, with advances in our understanding of pathophysiological and molecular mechanisms, many new therapeutic strategies (synthetic prostacyclin and prostacyclin analogues, endothelin receptor antagonists and sildenafil) have been developed for the treatment of PAH, and the clinical efficacy has been tested in many randomized-controlled trials (RCTs). In this overview, we review the evidence for the use of historical and new treatments that arises from the Cochrane Collaboration of Systematic Reviews and from recent RCTs.

Keywords

Pulmonary arterial hypertension
Prostacyclin
Endothelin receptor antagonists
Sildenafil

Cited by (0)

☆

The following Cochrane reviews have been cited in this evidence-based review. Paramothayan NS, et al. Prostacyclin for pulmonary hypertension in adults, Issue 2, 2005; Liu C, et al. Endothelin receptor antagonists for pulmonary arterial hypertension. Issue 1, 2005; Kanthapillai P, et al. Sildenafil for pulmonary hypertension, Issue 4, 2004.

Copyright © 2006 Elsevier Ltd. All rights reserved.